Virax Cash Ratio vs Free Cash Flow Analysis

VRAX Stock

USD 1.97 0.10 4.83%

Virax Biolabs financial indicator trend analysis is much more than just breaking down Virax Biolabs Group prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Virax Biolabs Group is a good investment. Please check the relationship between Virax Biolabs Cash Ratio and its Free Cash Flow accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Virax Biolabs Group. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

Cash Ratio vs Free Cash Flow

Cash Ratio vs Free Cash Flow Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Virax Biolabs Group Cash Ratio account and Free Cash Flow. At this time, the significance of the direction appears to have pay attention.

The correlation between Virax Biolabs' Cash Ratio and Free Cash Flow is -1.0. Overlapping area represents the amount of variation of Cash Ratio that can explain the historical movement of Free Cash Flow in the same time period over historical financial statements of Virax Biolabs Group, assuming nothing else is changed. The correlation between historical values of Virax Biolabs' Cash Ratio and Free Cash Flow is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cash Ratio of Virax Biolabs Group are associated (or correlated) with its Free Cash Flow. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Free Cash Flow has no effect on the direction of Cash Ratio i.e., Virax Biolabs' Cash Ratio and Free Cash Flow go up and down completely randomly.

Correlation Coefficient

-1.0

Relationship Direction	Negative
Relationship Strength	Strong

View All Relationships

Cash Ratio

Free Cash Flow

The amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.

Most indicators from Virax Biolabs' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Virax Biolabs Group current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Virax Biolabs Group. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

At this time, Virax Biolabs' Enterprise Value Over EBITDA is fairly stable compared to the past year. Enterprise Value Multiple is likely to rise to 0.30 in 2024, whereas Selling General Administrative is likely to drop slightly above 2.7 M in 2024.

	2021	2022	2023	2024 (projected)
Interest Expense	15.4K	15.5K	26.9K	28.3K
Depreciation And Amortization	1.7M	1.0	103.1K	97.9K

Interest Expense Depreciation And Amortization

Virax Biolabs fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Total Liab	Net Invested Capital	Total Current Assets	Capital Stock	Net Working Capital	Short Term Debt	Common Stock	Other Assets	Short Term Investments	Non Currrent Assets Other	Property Plant And Equipment Gross	Short Long Term Debt
Total Assets		-0.59	-0.62	-0.61	0.97	0.86	0.7	-0.98	-0.76	-0.32	0.99	0.99	0.39	-0.38	-0.63	0.97	1.0	0.73	1.0	-0.62	0.73	0.47	0.85	0.45	0.47	-0.38
Short Long Term Debt Total	-0.59		0.88	0.63	-0.64	-0.63	-0.98	0.65	0.67	-0.29	-0.56	-0.56	-0.37	-0.35	0.65	-0.64	-0.57	-0.74	-0.6	0.99	-0.74	-0.44	-0.59	-0.46	-0.44	0.44
Other Current Liab	-0.62	0.88		0.89	-0.73	-0.85	-0.94	0.64	0.92	0.01	-0.54	-0.54	-0.7	-0.21	0.89	-0.73	-0.58	-0.95	-0.62	0.94	-0.95	-0.79	-0.83	-0.82	-0.79	0.78
Total Current Liabilities	-0.61	0.63	0.89		-0.75	-0.9	-0.76	0.59	0.95	0.45	-0.51	-0.51	-0.81	0.18	1.0	-0.74	-0.55	-0.93	-0.6	0.74	-0.93	-0.9	-0.89	-0.95	-0.9	0.89
Total Stockholder Equity	0.97	-0.64	-0.73	-0.75		0.95	0.77	-0.97	-0.86	-0.37	0.95	0.95	0.47	-0.35	-0.77	1.0	0.96	0.85	0.97	-0.69	0.85	0.58	0.9	0.61	0.58	-0.58
Net Tangible Assets	0.86	-0.63	-0.85	-0.9	0.95		0.78	-0.85	-0.97	-0.43	0.81	0.81	0.67	-0.28	-0.91	0.95	0.83	0.95	0.86	-0.72	0.95	0.79	0.96	0.83	0.79	-0.79
Current Deferred Revenue	0.7	-0.98	-0.94	-0.76	0.77	0.78		-0.74	-0.81	0.12	0.66	0.66	0.5	0.22	-0.78	0.76	0.68	0.86	0.7	-0.99	0.86	0.58	0.74	0.61	0.58	-0.57
Net Debt	-0.98	0.65	0.64	0.59	-0.97	-0.85	-0.74		0.74	0.25	-0.99	-0.99	-0.29	0.32	0.62	-0.97	-0.99	-0.73	-0.99	0.66	-0.73	-0.4	-0.79	-0.42	-0.4	0.4
Retained Earnings	-0.76	0.67	0.92	0.95	-0.86	-0.97	-0.81	0.74		0.33	-0.67	-0.67	-0.79	0.12	0.94	-0.86	-0.71	-0.99	-0.75	0.77	-0.99	-0.88	-0.96	-0.92	-0.88	0.85
Accounts Payable	-0.32	-0.29	0.01	0.45	-0.37	-0.43	0.12	0.25	0.33		-0.28	-0.28	-0.35	0.91	0.45	-0.37	-0.3	-0.21	-0.32	-0.18	-0.21	-0.4	-0.42	-0.42	-0.4	0.39
Cash	0.99	-0.56	-0.54	-0.51	0.95	0.81	0.66	-0.99	-0.67	-0.28		1.0	0.25	-0.39	-0.54	0.95	1.0	0.66	0.99	-0.57	0.66	0.34	0.76	0.34	0.34	-0.3
Cash And Short Term Investments	0.99	-0.56	-0.54	-0.51	0.95	0.81	0.66	-0.99	-0.67	-0.28	1.0		0.25	-0.39	-0.54	0.95	1.0	0.66	0.99	-0.57	0.66	0.34	0.76	0.34	0.34	-0.3
Common Stock Shares Outstanding	0.39	-0.37	-0.7	-0.81	0.47	0.67	0.5	-0.29	-0.79	-0.35	0.25	0.25		-0.07	-0.79	0.46	0.31	0.74	0.38	-0.49	0.74	0.98	0.81	0.88	0.98	-0.67
Non Current Liabilities Total	-0.38	-0.35	-0.21	0.18	-0.35	-0.28	0.22	0.32	0.12	0.91	-0.39	-0.39	-0.07		0.2	-0.35	-0.39	0.01	-0.39	-0.3	0.01	-0.1	-0.27	-0.08	-0.1	0.06
Total Liab	-0.63	0.65	0.89	1.0	-0.77	-0.91	-0.78	0.62	0.94	0.45	-0.54	-0.54	-0.79	0.2		-0.76	-0.58	-0.92	-0.63	0.76	-0.92	-0.88	-0.89	-0.93	-0.88	0.88
Net Invested Capital	0.97	-0.64	-0.73	-0.74	1.0	0.95	0.76	-0.97	-0.86	-0.37	0.95	0.95	0.46	-0.35	-0.76		0.96	0.84	0.97	-0.69	0.84	0.57	0.89	0.61	0.57	-0.58
Total Current Assets	1.0	-0.57	-0.58	-0.55	0.96	0.83	0.68	-0.99	-0.71	-0.3	1.0	1.0	0.31	-0.39	-0.58	0.96		0.69	1.0	-0.59	0.69	0.4	0.8	0.39	0.4	-0.34
Capital Stock	0.73	-0.74	-0.95	-0.93	0.85	0.95	0.86	-0.73	-0.99	-0.21	0.66	0.66	0.74	0.01	-0.92	0.84	0.69		0.73	-0.83	1.0	0.84	0.93	0.89	0.84	-0.85
Net Working Capital	1.0	-0.6	-0.62	-0.6	0.97	0.86	0.7	-0.99	-0.75	-0.32	0.99	0.99	0.38	-0.39	-0.63	0.97	1.0	0.73		-0.62	0.73	0.46	0.84	0.44	0.46	-0.37
Short Term Debt	-0.62	0.99	0.94	0.74	-0.69	-0.72	-0.99	0.66	0.77	-0.18	-0.57	-0.57	-0.49	-0.3	0.76	-0.69	-0.59	-0.83	-0.62		-0.83	-0.57	-0.69	-0.6	-0.57	0.56
Common Stock	0.73	-0.74	-0.95	-0.93	0.85	0.95	0.86	-0.73	-0.99	-0.21	0.66	0.66	0.74	0.01	-0.92	0.84	0.69	1.0	0.73	-0.83		0.84	0.93	0.89	0.84	-0.85
Other Assets	0.47	-0.44	-0.79	-0.9	0.58	0.79	0.58	-0.4	-0.88	-0.4	0.34	0.34	0.98	-0.1	-0.88	0.57	0.4	0.84	0.46	-0.57	0.84		0.87	0.96	1.0	-0.8
Short Term Investments	0.85	-0.59	-0.83	-0.89	0.9	0.96	0.74	-0.79	-0.96	-0.42	0.76	0.76	0.81	-0.27	-0.89	0.89	0.8	0.93	0.84	-0.69	0.93	0.87		0.84	0.87	-0.71
Non Currrent Assets Other	0.45	-0.46	-0.82	-0.95	0.61	0.83	0.61	-0.42	-0.92	-0.42	0.34	0.34	0.88	-0.08	-0.93	0.61	0.39	0.89	0.44	-0.6	0.89	0.96	0.84		0.96	-0.94
Property Plant And Equipment Gross	0.47	-0.44	-0.79	-0.9	0.58	0.79	0.58	-0.4	-0.88	-0.4	0.34	0.34	0.98	-0.1	-0.88	0.57	0.4	0.84	0.46	-0.57	0.84	1.0	0.87	0.96		-0.8
Short Long Term Debt	-0.38	0.44	0.78	0.89	-0.58	-0.79	-0.57	0.4	0.85	0.39	-0.3	-0.3	-0.67	0.06	0.88	-0.58	-0.34	-0.85	-0.37	0.56	-0.85	-0.8	-0.71	-0.94	-0.8

Click cells to compare fundamentals

Virax Biolabs Account Relationship Matchups

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

Additional Tools for Virax Stock Analysis

When running Virax Biolabs' price analysis, check to measure Virax Biolabs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Virax Biolabs is operating at the current time. Most of Virax Biolabs' value examination focuses on studying past and present price action to predict the probability of Virax Biolabs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Virax Biolabs' price. Additionally, you may evaluate how the addition of Virax Biolabs to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Virax Cash Ratio vs Free Cash Flow Analysis

Cash Ratio vs Free Cash Flow

Cash Ratio vs Free Cash Flow Correlation Analysis

Correlation Coefficient

Cash Ratio

Free Cash Flow

Virax Biolabs fundamental ratios Correlations

Virax Biolabs Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Also Currently Popular

Additional Tools for Virax Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Total Assets
Net Working Capital	+ 1.0	Total Assets
Total Liab	+ 1.0	Total Current Liabilities
Net Invested Capital	+ 1.0	Total Stockholder Equity
Cash And Short Term Investments	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash

Common Stock	- 0.99	Retained Earnings
Capital Stock	- 0.99	Retained Earnings
Net Working Capital	- 0.99	Net Debt
Total Current Assets	- 0.99	Net Debt
Cash And Short Term Investments	- 0.99	Net Debt
Cash	- 0.99	Net Debt